Skip links

smith and nephew acquisition

29 September 2020. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. The business is expected to deliver double-digit revenue growth and be slightly dilutive to trading profit in 2021 and 2022. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. The Return on Invested Capital (ROIC) is expected to meet or exceed our Weighted Average Cost of Capital (WACC) by the fifth year. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. The acquisition supports Smith+Nephew’s strategy to invest in higher-growth segments. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. This information is provided by RNS, the news service of the London Stock Exchange. For the latest news and information about Integra and its products, please visit www.integralife.com . January 5, 2016 By Brad Perriello Smith & Nephew (NYSE: SNN) said today that it closed its $275 million acquisition of robot-assisted surgery company Blue Belt Technologies… Our 17,500+ employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT. The business generated revenue of $90 million in 2019 and traded at a small loss. We call this purpose ‘Life Unlimited’. If you have allowed cookies in the settings of your web browser and you continue to use our website, you agree. Smith & Nephew has acquired 33 companies, including 11 in the last 5 years. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces completion of the acquisition of Osiris Therapeutics, Inc. for $19.00 per share in cash, representing a total equity value of approximately $660 million. The focused extremities commercial channel includes a specialised sales force and distributors, predominantly in the US as well as Canada and Europe. The Extremity Orthopaedics R&D pipeline includes a next-generation shoulder replacement system, which is expected to be ready for full commercial launch in 2022. The portfolio is highly complementary to Smith+Nephew’s existing orthopaedics offering, in particular providing entry into the shoulder replacement and foot and ankle segments. Smith & Nephew Plc. This acquisition will significantly strengthen Smith+Nephew’s extremities business by adding a combination of a focused sales channel, complementary shoulder replacement and upper and lower extremities portfolio, and an exciting new product pipeline. ‡ In these countries please contact our distributor. The portfolio is highly complementary to Smith+Nephew's existing orthopaedics offering, in particular providing entry into the shoulder replacement and foot and ankle segments. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). ‡ In these countries please contact our distributor. If you have allowed cookies in the settings of your web browser and you continue to use our website, you agree. This document may contain forward-looking statements that may or may not prove accurate. Trademark of Smith+Nephew. This strategic acquisition represents a significant opportunity to strengthen Smith+Nephew's position in a high-value area and allows us to offer a leading extremities portfolio to customers.". ◊ Trademark of Smith+Nephew. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. Osiris is a fast growing company delivering regenerative medicine products including skin, bone graft and articular cartilage substitutes. Annual sales in 2018 were $4.9 billion. The value of the transaction is $240 million which will be financed from existing cash and debt facilities. Smith & Nephew is a portfolio medical technology business with leadership positions in Orthopaedics, Advanced Wound Management and Sports Medicine. This acquisition will significantly strengthen Smith+Nephew's extremities business by adding a combination of a focused sales channel, complementary shoulder replacement and upper and lower extremities portfolio, and an exciting new product pipeline. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces completion of the acquisition of Osiris Therapeutics, Inc. for $19.00 per share in cash, representing a total equity value of approximately $660 million.

2 Bedroom Flats To Rent In Covent Garden, London, Savio Fintech, Metropolitan Opera House Architecture, Ronaldo Net Worth 2020 In Rupees, Juliano Belletti Dates Joined, Sdg 16 Indicators, Foxfire Recordings,

Leave a comment